Clinical Trial Update: Gefitinib Plus Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Bladder Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating gefitinib in combination chemotherapy for locally advanced or metastatic bladder cancer (urothelial carcinoma).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Urothelial Carcinoma of the Renal Pelvis
• Urothelial Carcinoma of the Ureter

Drugs mentioned

• Gefitinib (Iressa) (gefitinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter | Phase 2 | Status: COMPLETED